LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

ACADIA Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

21.63 -0.6

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

21.38

Максимум

21.95

Ключови измерители

By Trading Economics

Приходи

-125M

19M

Продажби

-15M

244M

P/E

Средно за сектора

16.277

51.748

EPS

0.11

Марж на печалбата

7.771

Служители

653

EBITDA

7.1M

19M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+32.15% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

443M

3.7B

Предишно отваряне

22.23

Предишно затваряне

21.63

Настроения в новините

By Acuity

50%

50%

177 / 380 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

ACADIA Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.06.2025 г., 22:33 ч. UTC

Придобивния, сливания и поглъщания

Millicom to Acquire Telefonica Ecuador for $380 Million

13.06.2025 г., 23:50 ч. UTC

Придобивния, сливания и поглъщания

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13.06.2025 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13.06.2025 г., 23:09 ч. UTC

Придобивния, сливания и поглъщания

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13.06.2025 г., 23:03 ч. UTC

Придобивния, сливания и поглъщания

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13.06.2025 г., 22:18 ч. UTC

Придобивния, сливания и поглъщания

Millicom to Acquire Telefonica Ecuador for $380M

13.06.2025 г., 22:04 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Better Data Facilitate Investments In Oil Patch -- Market Talk

13.06.2025 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13.06.2025 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

Bunge: Outside Date Extended to July 3

13.06.2025 г., 21:35 ч. UTC

Придобивния, сливания и поглъщания

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13.06.2025 г., 21:34 ч. UTC

Придобивния, сливания и поглъщания

Bunge Gets Mexico Approval for Viterra Deal

13.06.2025 г., 21:32 ч. UTC

Придобивния, сливания и поглъщания

Bunge Gets China Approval for Viterra Deal

13.06.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

13.06.2025 г., 20:45 ч. UTC

Придобивния, сливания и поглъщания

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13.06.2025 г., 20:34 ч. UTC

Придобивния, сливания и поглъщания

Anne Wojcicki Wins Bidding for 23andMe -- Update

13.06.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13.06.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13.06.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13.06.2025 г., 19:30 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13.06.2025 г., 19:12 ч. UTC

Пазарно говорене

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13.06.2025 г., 19:04 ч. UTC

Пазарно говорене

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13.06.2025 г., 18:54 ч. UTC

Пазарно говорене

Correction to Gold Settles Market Talk

13.06.2025 г., 18:01 ч. UTC

Пазарно говорене

Gold Settles at Record High -- Market Talk

13.06.2025 г., 17:40 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13.06.2025 г., 17:21 ч. UTC

Пазарно говорене

Dollar Index, Commodities Rise -- Market Talk

13.06.2025 г., 17:02 ч. UTC

Придобивния, сливания и поглъщания

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13.06.2025 г., 17:02 ч. UTC

Придобивния, сливания и поглъщания

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13.06.2025 г., 17:02 ч. UTC

Придобивния, сливания и поглъщания

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13.06.2025 г., 17:02 ч. UTC

Придобивния, сливания и поглъщания

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

13.06.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

ACADIA Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

32.15% нагоре

12-месечна прогноза

Среден 28.73 USD  32.15%

Висок 37 USD

Нисък 18 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за ACADIA Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

17 ratings

14

Купи

3

Задържане

0

Продай

Техническа оценка

By Trading Central

14.845 / N/AПодкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Strong Bearish Evidence

Дългосрочен план

Neutral Evidence

Настроение

By Acuity

177 / 380 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.